Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00214266 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00214266 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 31 participants.
The verdict
NCT00214266, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The hypothesis of this study is that lymphocyte depletion by Campath-1H and rituximab will obviate the need for long-term calcineurin inhibitors in renal transplantation. Most successful strategies to date have relied on the use of either tacrolimus or cyclosporine. However, the advantage of a calcineurin inhibitor free regimen may include improved renal allograft function, a lower incidence of hypertension, diabetes, and less drug related side effects. This is a non-randomized open-label pilot trial in 30 adult renal transplant patients.
Interventions
- DRUG Campath 1H®, Rituximab, mycophenolate mofetil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00214266
The ClinicalTrials.gov registry entry for NCT00214266 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Campath 1H®, Rituximab, mycophenolate mofetil is the first listed.
NCT00214266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00214266 about?
NCT00214266 is a clinical study titled "A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation". The hypothesis of this study is that lymphocyte depletion by Campath-1H and rituximab will obviate the need for long-term calcineurin inhibitors in renal transplantation. Most successful strategies to date have relied on the use of either tacrolimus or cyclosporine. However, the advantage of a calci...
What is the current status of trial NCT00214266?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2005-01. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00214266?
The interventions under investigation include: Campath 1H®, Rituximab, mycophenolate mofetil (DRUG).
Who is sponsoring clinical trial NCT00214266?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.